Compositions of grapiprant and methods for using the same
The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.
1. A method of using grapiprant for treating osteoarthritis in a companion animal in need thereof, the method comprising administering to a companion animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant, sodium lauryl sulfate as a surfactant, and at least one excipient; wherein the therapeutically effective amount of grapiprant is orally administered at a dosage rate of 2 mg per kilogram bodyweight of the companion animal per day, wherein the companion animal is a dog or a cat, and wherein the administrating causes no clinically significant adverse gastrointestinal event or changes in liver, kidney, and coagulation parameters in the companion animal.
2. The method of claim 1 , wherein the administering achieves a C max of grapiprant of 375 ng/mL to 10000 ng/mL at a T max of 0.4 to 3.4 hours.
3. The method of claim 2 , wherein the administering achieves a C max of grapiprant of 750 ng/mL to 4000 ng/mL.
4. The method of claim 3 , wherein the administering achieves a C max of grapiprant of 1300 ng/mL to 4000 ng/mL.
5. The method of claim 2 , wherein the administering achieves the C max of grapiprant at a T max of 0.7 to 1.7 hours.
6. The method of claim 2 , wherein the administering achieves the C max of grapiprant at a T max of 0.5 to 1.0 hours.
7. The method of claim 1 , wherein the pharmaceutical composition further comprises 1% to 30% flavorant (w/w of the total composition).
8. The method of claim 7 , wherein the pharmaceutical composition comprises 5% to 15% flavorant (w/w of the total composition).
9. The method of claim 1 , wherein the pharmaceutical composition is administered at least once daily.
10. The method of claim 9 , wherein the pharmaceutical composition is administered at least twice daily.
11. The method of claim 1 , wherein the pharmaceutical composition is administered for 6 days to 9 months.
12. The method of claim 11 , wherein the pharmaceutical composition is administered for 9 to 21 days.
13. The method of claim 12 , wherein the pharmaceutical composition is administered for 12 to 14 days.
14. The method of claim 1 , wherein the pharmaceutical formulation is administered once daily at a dosage rate of 2 mg per kilogram bodyweight of the companion animal per day for 9 to 21 days.
15. The method of claim 14 , wherein the administering achieves a C max of grapiprant of 750 ng/mL to 4000 ng/mL at a T max of 0.7 to 1.7 hours.
16. The method of claim 1 , wherein the pharmaceutical formulation is administered twice daily at a dosage rate of 2 mg per kilogram bodyweight of the companion animal per day for 9 to 21 days.
17. The method of claim 16 , wherein the administering achieves a C max of grapiprant of 750 ng/mL to 4000 ng/mL at a T max of 0.7 to 1.7 hours.
18. The method of claim 16 , wherein the administering occurs from about 10 hours to about 18 hours before a surgery is performed on the companion animal.
19. A method of using grapiprant for treating pain or inflammation in a cat in need thereof, the method comprising orally administering to a cat a pharmaceutical composition comprising a therapeutically effective amount of grapiprant, sodium lauryl sulfate as a surfactant, and at least one excipient;
wherein the therapeutically effective amount of grapiprant is orally administered at a dosage rate 2 mg per kilogram bodyweight of the cat per day;
wherein the administering achieves a C max of grapiprant of 1000 ng/mL to 10000 ng/mL, a T max between 0.7 hours and 1.7 hours, and a half-life between 1.1 hours and 5 hours; and
wherein the administrating causes no clinically significant adverse gastrointestinal event or changes in liver, kidney, and coagulation parameters in the companion animal.
20. The method of claim 19 , wherein the pharmaceutical formulation is administered once daily at a dosage rate of 2 mg per kilogram bodyweight of the cat per day for 28 days.
21. The method of claim 19 , wherein the therapeutically effective amount of grapiprant is administered at a dosage rate of about 2 mg per kilogram body weight of the cat per day under fasting conditions, and wherein the administrating achieves a C max of grapiprant between 1100 ng/mL and 1630 ng/mL, a T max of about 1 hour, and a half-life between 1.5 hours and 2.2 hours.
22. The method of claim 19 , wherein the pharmaceutical composition further comprises 1% to 30% flavorant (w/w of the total composition).
23. The method of claim 22 , wherein the pharmaceutical composition comprises 5% to 15% flavorant (w/w of the total composition).
24. The method of claim 19 , wherein the pharmaceutical composition is administered at least once daily.
25. The method of claim 24 , wherein the pharmaceutical composition is administered at least twice daily.
26. The method of claim 19 , wherein the pharmaceutical composition is administered for 6 days to 9 months.
27. The method of claim 26 , wherein the pharmaceutical composition is administered for 9 to 21 days.
28. The method of claim 27 , wherein the pharmaceutical composition is administered for 12 to 14 days.
29. The method of claim 19 , wherein the pharmaceutical formulation is administered once daily at a dosage rate of 2 mg per kilogram bodyweight of the cat per day for 9 to 21 days.
30. The method of claim 19 , wherein the pharmaceutical formulation is administered twice daily at a dosage rate of 2 mg per kilogram bodyweight of the cat per day for 9 to 21 days.
31. The method of claim 30 , wherein the administering occurs from about 10 hours to about 18 hours before a surgery is performed on the cat.
32. A method of using grapiprant for treating pain or inflammation in a dog in need thereof, the method comprising orally administering to a dog a pharmaceutical composition comprising a therapeutically effective amount of grapiprant, sodium lauryl sulfate as a surfactant, and at least one excipient;
wherein the therapeutically effective amount of grapiprant is administered at a dosage rate of 2 mg per kilogram bodyweight of the dog per day, and wherein the administering achieves a C max of grapiprant between 1270 ng/mL and 2460 ng/mL, a T max between 0.7 hours and 1 hour, and a half-life between 3.1 and 9.2 hours; and
wherein the administrating causes no clinically significant adverse gastrointestinal event or changes in liver, kidney, and coagulation parameters in the companion animal.
33. The method of claim 32 , wherein the pharmaceutical composition further comprises 1% to 30% flavorant (w/w of the total composition).
34. The method of claim 33 , wherein the pharmaceutical composition comprises 5% to 15% flavorant (w/w of the total composition).
35. The method of claim 32 , wherein the pharmaceutical composition is administered at least once daily.
36. The method of claim 35 , wherein the pharmaceutical composition is administered at least twice daily.
37. The method of claim 32 , wherein the pharmaceutical composition is administered for 6 days to 9 months.
38. The method of claim 37 , wherein the pharmaceutical composition is administered for 9 to 21 days.
39. The method of claim 38 , wherein the pharmaceutical composition is administered for 12 to 14 days.
40. The method of claim 32 , wherein the pharmaceutical formulation is administered once daily at a dosage rate of 2 mg per kilogram bodyweight of the dog per day for 9 to 21 days.
41. The method of claim 32 , wherein the pharmaceutical formulation is administered twice daily at a dosage rate of 2 mg per kilogram bodyweight of the dog per day for 9 to 21 days.
42. The method of claim 32 , wherein the administering occurs from about 10 hours to about 18 hours before a surgery is performed on the dog.
43. The method of claim 32 , wherein the administrating further achieves a mean area under the curve (AUC 0-∞ ) between 2840 hr*ng/mL and 5160 hr*ng/mL.
44. The method of claim 43 , wherein the administrating achieves a C max of grapiprant between 1430 ng/mL and 2460 ng/mL, a T max of about 0.7 hours, a half-life between 6.4 hours and 9.2 hours, and a mean AUC 0-∞ between 3190 hr*ng/mL and 5160 hr*ng/mL.
45. The method of claim 43 , wherein the administrating achieves a C max of grapiprant between 1270 ng/mL and 1900 ng/mL, a T max between 0.7 hours and 0.9 hours, a half-life between 3.1 hours and 6.8 hours, and a mean AUC 0-∞ between 3190 hr*ng/mL and 5160 hr*ng/mL.
46. The method of claim 43 , wherein the administrating achieves a C max of grapiprant between 1430 ng/mL and 2160 ng/mL, a T max between 0.8 hours and 0.9 hours, a half-life between 5.2 hours and 7.4 hours, and a mean AUC 0-∞ between 2860 hr*ng/mL and 3410 hr*ng/mL.
47. The method of claim 43 , wherein the administrating achieves a C max of grapiprant between 1750 ng/mL and 5180 ng/mL, a T max of about 0.9 hours, a half-life between 5.7 hours and 6.9 hours, and a mean AUC 0-∞ between 4420 hr*ng/mL and 4650 hr*ng/mL.
48. The method of claim 32 , wherein the dog has osteoarthritis.
49. The method of any one of the claims 1 , 19 , or 32 , wherein the at least one excipient consists of lactose, microcrystalline cellulose, sodium starch glycolate, copovidone, magnesium stearate, colloidal silicon oxide, or a combination thereof.